Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521143-20-00

Enrollment

Registered

2026-09-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Morphogenic Protein Receptor type 2 mutation carriers Chronic Kidney Disease Idiopathic Pulmonary Fibrosis Metabolic dysfunction-associated Steatotic Liver Disease Pulmonary Arterial Hypertension Primary Sclerosing Cholangitis

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 11, 2026

Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)

Conditions

Related papers

Interventions

Sponsors

Eligibility

Outcome results